Evidence map›Paper›PMID 39977417›Full record

SynthesisPloS one2025

Proton or photon? Comparison of survival and toxicity of two radiotherapy modalities among pediatric brain cancer patients: A systematic review and meta-analysis.

Renáta Kiss-Miki, Mahmoud Obeidat, Vanda Máté, Brigitta Teutsch, Gergely Agócs, Szilvia Kiss-Dala, Péter Hegyi, Janka Kovács, Andrea Párniczky, Eszter Tuboly and 1 more

Abstract readSystematic ReviewMeta-AnalysisComparative Study
In one paragraph

Synthesis in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Relative biological effectiveness and neural stem cell fate in carbon ion-irradiated human brain organoids.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2026
    Article
  7. Review
  8. Article
  9. Advances in Radiation Therapy for Primary Bone Malignancies.Technology in cancer research & treatment
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Renáta Kiss-MikiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Mahmoud ObeidatCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0002-2861-2573
Vanda MátéCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Brigitta TeutschCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Gergely AgócsCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Szilvia Kiss-DalaCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Janka KovácsCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Andrea PárniczkyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0003-3466-4780
Eszter TubolyCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0003-0333-6952
Miklós GaramiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.ORCID 0000-0003-4298-2746

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the introduction of new therapy modalities and the resulting increase in survival rates, childhood brain cancers have become a focal point of research in pediatric oncology. In current protocols, besides surgical resection and chemotherapy, radiotherapy is required to ensure optimal survival. Our aim was to determine which of the two major irradiation options, proton (PT) or photon (XRT), was the least harmful yet effective for children with brain tumors.

methodsThe protocol was registered on PROSPERO in advance (CRD42022374443). A systematic search was performed in four databases (MEDLINE via (PubMed), Embase, Cochrane Library, and Scopus) on 23 April 2024. Odd ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effects model. Survival and six major types of side effects were assessed based on data in the articles and reported using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Heterogeneity was assessed using Higgins and Thompson's I2 statistics.

resultsAltogether, 5848 articles were screened, of which 33 were eligible for data extraction. The 5-year overall survival results showed statistically no significant difference between the two radiotherapy modalities (OR = 0.80, 95% CI: 0.51-1.23, p = 0.22, I2 = 0%). In terms of toxicity rates, an advantage was found for PT, particularly in terms of chronic endocrine side effects (hypothyroidism OR: 0.22, 95% CI: 0.10-0428, p = 0.002, I2 = 68%), neurocognitive decline (global IQ level MD: 13.06, 95% CI: 4.97-21.15, p = 0.009, I2 = 68%). As for hematological, acute side effects, neurological changes and ophthalmologic disorders PT can be beneficial for survivors in terms of reducing them.

conclusionsIn comparison with XRT, PT can reduce most side effects, without significantly decreasing the survival rate. There is considerable clinical relevance in the findings, even not all of them are statistically significant, which may facilitate the development of protocols regarding the usage of radiotherapy methods, and may encourage the establishment of more proton centers, where more studies can be done.

Indexed as

Brain NeoplasmsPhotonsProton TherapyChildHumansSurvival Rate

Identifiers

PMID39977417
PMCPMC11841876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.